ACCELERATING DISCOVERY AND DEVELOPMENT OF NEW PRODUCTS ADDRESSING UNMET CLINICAL NEED.
VIC explores and develops new ways to modulate the immune system for therapeutic benefit. Our approach is deeply collaborative and involves leveraging the expertise and direct involvement of academic and industry scientists from US and abroad. We currently have nine products in our pipeline ranging from small molecule immune modulators for specific cancers through a vaccine in development for Q fever to a novel microencapsulant to enable allogeneic cell or tissue transplantation without immune suppression.
VIC supports rapid-pace, high-impact research initiatives that are in the process of safely transitioning from the research lab to patients
Accelerating innovation relies on two things; the disciplined focus on the VIC mission and the generosity of donors who share our goals. Development of our new vaccines and immunotherapies can only be achieved with additional support beyond grants and contracts. We are very grateful to our donors for their visionary support of our scientists and the work at VIC.